News und Analysen
Why Juno Therapeutics Shares Are Going Up 21.2% Today
After the company released its third-quarter progress report and shared the latest data from its lead drug, JCAR017, shares of Juno Therapeutics (NASDAQ: JUNO) are shooting 21.2% higher at 2:30....
Here's Why Alnylam's Gain Is Ionis Pharmaceuticals' Loss Today
As of 1:18 p.m. EDT on Thursday, shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) are up 13.7%, while shares of its biotech peer Ionis Pharmaceuticals Inc. (NASDAQ: IONS) are down....
Here's Why Myriad Genetics Dropped as Much as 18.6%
Shares of genetic-testing leader Myriad Genetics (NASDAQ: MYGN) dropped over 18% today. That may have investors confused, especially considering the company today announced that its GeneSight....
Here's Why Neurocrine Biosciences Is Soaring
In response to the company reporting better-than-expected quarterly results, shares of Neurocrine Biosciences (NASDAQ: NBIX), a commercial stage biotech focused on neurological and endocrine....
Juno Therapeutics' 3rd Quarter Boosted by Potential Rival Novartis
It's a great time to be a biotech focused on CAR-T (chimeric antigen receptor T-cell therapy). Juno Therapeutics (NASDAQ: JUNO) stock has soared so far in 2017, partially due to its own good....
Masimo Corporation's Mighty Momentum Continues in 3rd Quarter
Things looked so great for Masimo Corporation (NASDAQ: MASI) when it reported results from the second quarter in August that the company upped its full-year guidance. Revenue and earnings soared,....
Global Blood Therapeutics Inc. Jumped as Much as 14% on This News
Shares of San Francisco-based Global Blood Therapeutics (NASDAQ: GBT), a small-cap developer of experimental therapies focused on treating blood-based disorders, rocketed higher by as much as 14%....
The Clear Reason Alkermes Plc's Shares Jumped by as Much as 12%
Shares of Alkermes (NASDAQ: ALKS), an Irish-based commercial-stage drug developer with a focus on central nervous system medicines, jumped by as much as 12% during Thursday's trading session and....
Alkermes Reports Mixed Results, Updates Guidance
Alkermes (NASDAQ: ALKS), a commercial-stage biopharmaceutical company focused on diseases of the central nervous system, reported its third-quarter earnings results on Thursday, Oct. 26. While....
Here's Why NuVasive, Inc. Popped Today
Shares of NuVasive, Inc. (NASDAQ: NUVA), a spinal-surgery device manufacturer, popped as high as 9.8% Wednesday morning before settling back down to an 8.1% gain as of 3:07 p.m. A mixed....
Here's Why Acadia Healthcare Company Inc. Is Sinking Today
Shares of Acadia Healthcare Company Inc. (NASDAQ: ACHC) have fallen 25.6% as of 11:01 a.m. EDT on Wednesday after the company reported softer-than-expected results on Tuesday. The provider....
NuVasive's Sluggish Sales Growth Prompts Buybacks
Modern medicine has offered some revolutionary products and techniques, and many companies are looking to help sustain the pace of medical advances. NuVasive's (NASDAQ: NUVA) specialty in spinal....
3 Top Biotech Stocks to Buy Now
You should seriously consider adding a few biotech stocks to your portfolio if you don't already own some. Why? Because they give you an opportunity to make higher returns.And the good news is....
3 Arguments for and Against Legalizing Marijuana
There's arguably no industry in the U.S. that's growing at a faster, more consistent pace than legal marijuana. Marijuana Business Daily's latest report, "Marijuana Business Factbook 2017,"....
Better Buy: Exelixis, Inc. vs. Intra-Cellular Therapies Inc.
Biotech investors are always looking for the next big thing. That's exactly what they found in Exelixis (NASDAQ: EXEL), which ranked as one of the top biotech stocks of 2016 (and 2015 also). But....
Why uniQure N.V. Stock Is Hopping Today
Shares of the gene therapy company uniQure N.V. (NASDAQ: QURE) rose by as much as 27% in early-morning trading today on over 27 times the average volume. uniQure's stock is responding positively....
Why Marijuana Stocks Won't Pay a Dividend, Even if They're Profitable
There aren't too many industries that can grow at 20%-plus a year over the next five years, but marijuana could be one of them. Cannabis research firm ArcView believes the legal North American pot....
3 Small-Cap Biotech Stocks That Could Be Big Winners in 2018
Small-cap biotech stocks, or companies with valuations ranging from $300 million to $2 billion, can generate truly astonishing returns on capital in exceptionally short periods of time. Several of....
Why Exelixis' Rebound Is Just Getting Started
Exelixis (NASDAQ: EXEL) stock had been in the doldrums. After roaring for much of the first eight months of the year, the biotech's share price sank more than 15% during September. All of that is....
Where Will Opko Health Inc. Be in 5 Years?
Opko Health (NASDAQ: OPK) has had a rough year no matter how you look at it. So far in 2017, shares of the pharmaceutical and diagnostics company are down more than 20%. At one point, Opko stock....
Why Exelixis, Inc. Rose Higher Today
Exelixis (NASDAQ: EXEL) is up 24% at 12:21 p.m. EDT after announcing that the phase 3 Celestial trial met its primary endpoint of helping liver cancer patients taking Cabometyx live longer than....
3 Growth Stocks at Value Stock Prices
It's not surprising that after an eight-year bull market, some are saying value investing is dead. With the cyclically adjusted P/E ratio of the S&P running at a red-hot 31, finding a value....
3 Signs Myriad Genetics' High-Growth Days Are Over
Myriad Genetics (NASDAQ: MYGN) used to be the creme de la creme of the genetic testing industry. It had healthy profit margins, a growing business, and was well-known among investors and health....
Why CRISPR Therapeutics AG Stock Lost Ground in September
According to data from S&P Global Market Intelligence, shares of the gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) dropped by 13.1% in September. CRISPR's poor showing last month....
3 Monster Stocks in the Making
Halloween is right around the corner, which makes it the perfect time to look for monster stocks in the making. What are some characteristics these stocks might have? Leading market positions,....